Economic Evaluation of Lapatinib in Her-2-Positive Metastatic Breast Cancer Patients in Egypt.
نویسندگان
چکیده
Elsisi GH, Kaló Z, Eldessouki R, Elmahdawy MD, Saad A, Ragab S, Elshalakani A, Abaza. Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt. Value in Health RI 2013:2;319-327. Fig. 1: Markov State-transition Bubble diagram Economic Evaluation of Lapatinib in HER-2-Positive Metastatic Breast Cancer Patients in Egypt Gihan H. ElSisi1*, Esraa Saeed1, Abdalla Abo Taleb2. 1 Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Ministry of Health, Egypt 2 World Health Organization Consultant ISPOR 17th Annual European Congress November 8th -12th 2014, Amesterdam, Netherlands
منابع مشابه
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
PURPOSE Biomarkers from two randomized phase III trials were analyzed to optimize selection of patients for lapatinib therapy. EXPERIMENTAL DESIGN In available breast cancer tissue from EGF30001 (paclitaxel +/- lapatinib in HER-2-negative/unknown metastatic breast cancer, n = 579) and EGF100151 (capecitabine +/- lapatinib in HER-2-positive metastatic breast cancer, n = 399), HER-2 gene amplif...
متن کاملEvaluating Trastuzumab and Lapatinib’s Economic Impact in the Treatment of Metastatic Breast Cancer in Veneto Region Cohort
Objective: To assess the economic impact of the introduction of trastuzumab and lapatinib, as 1st and 2nd line treatment of HER-2 (Human Epidermal Growth Factor Receptor 2)-positive mBC (metastatic breast cancer) patients in Veneto region (North-East of Italy). Methods: A Markov state decision model was implemented to evaluate the cost impact of trastuzumab and lapatinib use for a lapse of time...
متن کاملTargeted treatment of advanced and metastaticbreast cancer with lapatinib
Improved molecular understanding of breast cancer in recent years has led to the discovery of important drug targets such as HER-2 and EGFR. Lapatinib is a potent dual inhibitor of HER-2 and EGFR. Preclinical and phase I studies have shown activity with lapatinib in a number of cancers, including breast cancer, and the drug is well tolerated. The main known drug interactions are with paclitaxel...
متن کاملLapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer
OBJECTIVE To evaluate the efficacy and tolerability of letrozole plus lapatinib versus letrozole plus placebo in women with hormone receptor (HR)(+) human epidermal growth factor receptor (HER)-2(+) tumors receiving first-line therapy for metastatic breast cancer (MBC). PATIENTS AND METHODS Postmenopausal women (n = 1,286) with HR(+) MBC were randomized to daily oral treatment with letrozole ...
متن کاملNearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation
Trastuzumab treatment does not prevent intracranial seeding and is largely ineffective for established central nervous system metastasis in HER2 overexpressing breast cancer patients. Combination therapy of lapatinib and capecitabine may be an effective treatment option for brain metastasis of HER2-positive breast cancer. We report a patient with breast cancer overexpressing HER-2 where brain m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 17 7 شماره
صفحات -
تاریخ انتشار 2014